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Abstract
Unmodified or as a poly[lactide-co-glycolide] nanoparticle, tetraiodothyroacetic acid (tetrac) acts at the integrin avb3
receptor on human cancer cells to inhibit tumor cell proliferation and xenograft growth. To study in vitro the
pharmacodynamics of tetrac formulations in the absence of and in conjunction with other chemotherapeutic agents, we
developed a perfusion bellows cell culture system. Cells were grown on polymer flakes and exposed to various
concentrations of tetrac, nano-tetrac, resveratrol, cetuximab, or a combination for up to 18 days. Cells were harvested and
counted every one or two days. Both NONMEM VI and the exact Monte Carlo parametric expectation maximization
algorithm in S-ADAPT were utilized for mathematical modeling. Unmodified tetrac inhibited the proliferation of cancer cells
and did so with differing potency in different cell lines. The developed mechanism-based model included two effects of
tetrac on different parts of the cell cycle which could be distinguished. For human breast cancer cells, modeling suggested a
higher sensitivity (lower IC50) to the effect on success rate of replication than the effect on rate of growth, whereas the
capacity (Imax) was larger for the effect on growth rate. Nanoparticulate tetrac (nano-tetrac), which does not enter into cells,
had a higher potency and a larger anti-proliferative effect than unmodified tetrac. Fluorescence-activated cell sorting
analysis of harvested cells revealed tetrac and nano-tetrac induced concentration-dependent apoptosis that was correlated
with expression of pro-apoptotic proteins, such as p53, p21, PIG3 and BAD for nano-tetrac, while unmodified tetrac showed
a different profile. Approximately additive anti-proliferative effects were found for the combinations of tetrac and
resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac and cetuximab. Our in vitro perfusion cancer cell system
together with mathematical modeling successfully described the anti-proliferative effects over time of tetrac and nano-
tetrac and may be useful for dose-finding and studying the pharmacodynamics of other chemotherapeutic agents or their
combinations.
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Introduction
Tetraiodothyroacetic acid (tetrac) is a deaminated thyroid
hormone analogue that binds to the integrin avb3 receptor for
thyroid hormone [1,2]. Tetrac inhibits binding of agonist L-
thyroxine, T4, and 3,5,39-triiodo-L-thyronine, T3, to the integrin on
cultured cells [1], blocking nongenomically-initiated effects of T4 and
T3 on signal transduction pathways [2–4]. Tetrac also has actions at
the receptor independent of T4 and T3, including inhibition of cancer
cell proliferation [2–4] and angiogenesis [5,6]. The integrin is largely
expressed on tumor cells and dividing blood vessel cells [7]. Acting at
the surface of cancer cells, tetrac alters expression of differentially-
regulated cancer cell survival pathway-relevant genes. These include
upregulation of expression of pro-apoptotic BcL-x short form [3] and
other pro-apoptotic genes [8], upregulation of anti-angiogenic
thrombospondin 1 and downregulation of several families of anti-
apoptotic genes [8,9]. Covalently bound to the exterior of a
nanoparticle, tetrac does not gain access to the cell interior—where
it may have thyromimetic activity [10]—and has biological activity at
the integrin receptor similar to that of unmodified tetrac, but with
desirable effects on cell survival pathway genes that differ from the
parent thyroid hormone analogue [8,9].
To further characterize in vitro the anti-proliferative pharmaco-
dynamics (PD) of tetrac and nanoparticulate tetrac (nano-tetrac),
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perfusion bellows cell culture system based on a perfusion (‘hollow
fiber’) model. The hollow fiber model was modified by two co-
authors (AL, GLD) from a previous system that explored antibiotic
pharmacodynamics [11]. The hollow fiber model and perfusion
bellows cell culture system allow simulation of concentration-time
profiles (pharmacokinetics) expected in humans in an in vitro
system and study of the effects over time (PD) of anti-infective and
anti-cancer agents in vitro [12,13]. Such in vitro systems in
combination with mathematical modeling can support translation
from in vitro to animal models and human clinical trials. The
developed pharmacodynamic model describes the full time course
of drug effects at various concentrations simultaneously and may
be used to predict the effects of other than the studied dosage
regimens.
We report here that tetrac and nano-tetrac inhibit cancer cell
proliferation on a concentration-dependent basis that can be cell
line-specific. Harvesting cancer cells from the perfusion bellows
cell culture system permits fluorescence-activated cell sorting
(FACS) analysis of cell cycle, and for apoptosis, quantitation of
specific pro-apoptotic and anti-apoptotic gene expression by
RT-PCR or microarray. Unmodified tetrac and nano-tetrac
were tested in this model system for anti-proliferative efficacy
alone or in combination with two other anticancer agents, the
stilbene resveratrol [14], and commercially-available anti-epi-
dermal growth factor receptor (EGFR) monoclonal antibody
(cetuximab, Erbitux). Additive effects were obtained with
combinations of tetrac or nano-tetrac and those other chemo-
therapeutic agents. We report studies in several human cancer
cell lines to infer the applicability of the model and to confirm,
not surprisingly, that there are dose-dependent differences in
responses of specific cell lines to the chemotherapeutic agents
tested.
Overall our aim to develop a mechanism-based pharmacody-
namic model that characterizes the action of tetrac on human
cancer cells in a newly developed perfusion bellows cell culture
system was well achieved as described in the present report.
Results
Action of tetraiodothyroacetic acid (tetrac) on cancer cell
proliferation
The pharmacodynamics of tetrac as an anti-proliferative agent
against human cancer cell lines were examined in the perfusion
bellows cell culture system depicted in Fig. 1. Stability of tetrac in
the culture system was determined by LC/MS/MS. Without cells,
75% of the original tetrac concentration was detected after 24 h
incubation in medium with 10% FBS at both room temperature
and 37uC. Tetrac decayed by 12% when incubated with cells at
37uC, indicating that tetrac is relatively stable in the perfusion
bellows cell culture system.
At first tetrac induced anti-proliferation of cancer cells was
studied in the non-perfusion system. Human glioblastoma U87MG
cells were treated with different tetrac concentrations (10
29–
10
25 M) for 7 d, with daily replenishment of tetrac. A model
incorporating effects of tetrac on both growth rate and success of
replication (Fig. 2) adequately described the time course of cell
counts as shown by comparison of the model fitted lines to the
observed data (Fig. 3A). Tetrac caused a concentration-dependent
reductioninU87MGcellproliferation(Fig. 3A), where10
29 M was
least effective, and 10
28 and 10
27 M caused 15% and 28%
decreases in cell counts compared to untreated cells after treatment
for 7 d (Fig. 3A). Both effects on growth rate and probability of
successful replication were required to describe inhibition of cell
proliferation of U87MG cells, as shown by a statistically significant
(p,0.01) difference in NONMEM’s objective function.
Parameter estimates suggested U87MG cells being more
sensitive to tetrac’s effect on growth rate than to the effect on
success of replication (IC50k,IC50R, Table 1). However, the
capacity (i.e. the largest possible effect at very high concentrations
of tetrac) was higher for the effect on success of replication than the
Figure 1. The perfusion bellows cell culture system. Cells of
cancer cell lines of interest are grown on plastic flakes suspended in a
flow-through, bellows-agitated system that allows for homogeneous
exposure of cells to drug/drug metabolite buffer solutions and air. The
system permits frequent sampling of cells for viability. The direction of
each arrow indicates the direction of influx and efflux of the culture
medium. Components of system are not drawn to scale.
doi:10.1371/journal.pcbi.1001073.g001
Author Summary
Clinical treatment protocols for specific solid cancers have
favorable response rates of 20%–25%. Cancer cells
frequently become resistant to treatment. Therefore, novel
anti-cancer drugs and combination regimens need to be
developed. Conducting enough clinical trials to evaluate
combinations of anti-cancer agents in several regimens to
optimize treatment is not feasible. We showed that tetrac
inhibits the growth of various cancer cell lines. Our newly
developed in vitro system allowed studying the effects of
tetrac over time in various human cancer cell lines. Our
mathematical model could distinguish two effects of tetrac
and may be used to predict effects of other than the
studied dosage regimens. Human breast cancer cells were
more sensitive to the effect on success of replication than
the effect on growth rate, whereas the maximum possible
effect was larger for the latter effect. Nanoparticulate
tetrac, which does not enter into cells, had a larger effect
than unmodified tetrac. The combinations of tetrac and
resveratrol, tetrac and cetuximab (Erbitux), and nano-tetrac
and cetuximab showed approximately additive effects. Our
in vitro perfusion system together with mathematical
modeling may be useful for dose-finding, translation from
in vitro to animal and human studies, and studying effects
of other chemotherapeutic agents or their combinations.
Tetrac Effects on Cancer Cells
PLoS Computational Biology | www.ploscompbiol.org 2 February 2011 | Volume 7 | Issue 2 | e1001073effect on rate of growth (ImaxR.Imaxk). For this model the cell
count on day 0 was fixed based on the number of seeded cells.
From simulation-estimation experiments (50 replicates, very rich
sampling, additive error on log10-scale=0.1) the median bias was
24% for Imaxk, +25% for IC50k, +0.4% for ImaxR, and 22%
for IC50R, using the MC-PEM algorithm in S-ADAPT. When the
same bootstrap datasets plus 50 additional ones were run in
NONMEM, the median bias was 22% for Imaxk, +16% for
IC50k, 22% for ImaxR and 27% for IC50R (nominal results
from NONMEM shown in Table 1). Bootstrap results for the
actual sampling times in the experiments were similar to those
from the rich design (Table 1). The two effects were therefore
estimable and distinguishable, both under ideal conditions and in
the actual sampling schedule which was employed in our
experiment. For additional model evaluation, S-ADAPT with
the MC-PEM algorithm was also used to estimate the parameters
from the observed data. The S-ADAPT results for ImaxR and
IC50R were within 15% of the results from NONMEM, while
Imaxk was 22% lower and IC50k was 70% higher than the results
from NONMEM. All other parameters were within 40% of their
NONMEM estimates. The satisfactory agreement of parameter
estimates from two completely different algorithms suggests
adequate estimability of the model parameters.
In addition, estrogen receptor-a (ERa)-negative human breast
cancer MDA-MB-231 cells (MDA-MB) were treated with 7 different
concentrations of tetrac (10
28 to 10
25 M) for 19 d and total cell
counts determined every 1–2 d (Fig. 3B). A model with effects on
both rate of growth and success of replication (Fig. 2) adequately
described the data (Fig. 3B). Parameter estimates from NONMEM
are shown in Table 1. The parameter estimates suggest a higher
sensitivity for the effect on probability of successful replication
(IC50R,IC50k, Table 1) and a larger capacity of the effect on
growth rate (Imaxk.ImaxR). Simulation-estimation experiments
(50 replicates, additive error on log10-scale=0.1) showed a median
bias of +3% for Imaxk, +9% for IC50k, 22% for ImaxR, and +6%
for IC50R, using the MC-PEM algorithm in S-Adapt. For 100
datasets in NONMEM the median bias was +0.5% for Imaxk,
20.4% for IC50k, +0.5% for ImaxR and +4% for IC50R. The
bootstrap results based on the actual sampling design which was also
rich were similar (Table 1). As for the action of tetrac on U87MG
cells, both effects were therefore estimable and distinguishable. In S-
ADAPT (MC-PEM), the parameter estimates based on the observed
data were within 20% of those from NONMEM for 5 parameters
and were within 50% for the other 3 parameters.
Although tetrac had a growth-suppressive effect late in the
treatment period, it may also have a proliferative effect on cancer
cells (results not shown here). This is thought to reflect access of the
agent to the cell interior where it is a modest thyroid hormone
agonist (thyromimetic) [9,10,15] rather than an inhibitor, as it is
exclusively at the cell surface receptor.
Anti-proliferative effects of nano-tetrac in cancer cells
To prevent uptake of tetrac by cancer cells, it was reformulated
as poly[lactide-co-glycolide] nanoparticle [8,9,16]. MDA-MB cells
were treated with constant concentrations of 10
26 and
2.5610
26 M tetrac or nano-tetrac for 9 d. Results indicate that
the anti-proliferative effect of nano-tetrac in MDA-MB cells is
greater than that of unmodified tetrac (Fig. 4A). MDA-MB cells
were also treated with 4 different concentrations of nano-tetrac
(10
29 to 10
26 M) for 9 d (Fig. 4B). Based on mathematical
modeling, the sensitivity of the MDA-MB cells for the nano-tetrac
effect on probability of successful replication was considerably
higher than for the effect on growth rate (IC50R=0.0086 mM,
IC50k=6.3 mM, Table 1), while the capacity was similar for both
effects (Imaxk=1.0, ImaxR=1.0 at time=0). Simulation-estima-
tion experiments (50 replicates, additive error on log10-scale=0.1)
showed a median bias of +12% for IC50k, 20.8% for kiR, and
+2.5% for IC50R, using the MC-PEM algorithm in S-ADAPT.
For 100 datasets in NONMEM the median bias was +4.0% for
IC50k, 22.5% for kiR, and 21.3% for IC50R. The bootstrap
results based on the actual sampling design are shown in Table 1.
The anti-proliferative effect of nano-tetrac was also concentra-
tion-dependent in human glioblastoma U87MG cells. At a nano-
tetrac concentration of 10
29 M, cell number was reduced
by 36% (control vs. 10
29 M nano-tetrac=1.45610
863.3610
7
vs. 2.28610
861.9610
7, average6S.D.) after 7 treatment days
(Fig. 4C). Modeling suggested a higher sensitivity for the effect on
rate of growth (IC50k,IC50R, Table 1) and a higher capacity for
the effect on replication (Imaxk , ImaxR). Both IC50k and
IC50R were lower for nano-tetrac than unmodified tetrac in
U87MG cells indicating a higher sensitivity to nano-tetrac. For
both MDA-MB and U87MG cells, the model includes a decrease
in ImaxR of nano-tetrac over time in order to adequately describe
the observed cell counts. Such a decrease in ImaxR might
potentially be due to functional adaptation or presence of
subpopulations with different sensitivities to tetrac. Simulation-
estimation experiments (50 replicates, additive error on log10-
scale=0.1) showed a median bias of +2.1% for Imaxk, 22.8% for
kiR, and +5.7% for IC50R, using the MC-PEM algorithm in
S-Adapt. For 100 datasets in NONMEM the median bias was
+1.5% for Imaxk, 21.5% for kiR, and +1.3% for IC50R. The
bootstrap results based on the actual sampling design are shown in
Table 1. The individual measurements presented as symbols in
Fig. 4B and 4C are the results from 3 repeat experiments, i.e. one
data point represents one experiment at each time point. The
error bars in Fig. 4A are standard deviations from 3 experiments.
The plots of observed versus predicted cell counts are presented
in Fig. 5 for unmodified and nano-tetrac in U87MG and MDA-
Figure 2. Diagram of the mathematical model. This model
assumes two populations of cells in different states of the cell cycle:
cells that are preparing for replication (State 1) and cells that are
immediately ‘pre-replication’ (State 2). Cells transition from State 1 to
State 2 by a first-order growth rate constant, while replication from
State 2 to State 1 is assumed to be rapid.
doi:10.1371/journal.pcbi.1001073.g002
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adequately described.
Apoptosis in tetrac-treated MDA-MB cells
Cells were harvested from the perfusion bellows cell culture
system for flow cytometry analysis after 1–3 d of treatment with
10
28 to 10
25 M tetrac. There was a 1.8-fold increase of apoptotic
cellswith10
25 Mtetraccomparedtountreatedcellsat1 d(Fig.6A).
By days 2 and 3, all tetrac concentrations caused apoptosis, as
determined by TUNEL assay. In cells continuously exposed to
tetrac for more than 10 d, only 10
25 M tetrac produced apoptosis
consistently (Fig. 6B), suggesting that tetrac may induce some cell
Figure 3. Tetrac suppresses proliferation of glioma and breast cancer cells. U87MG cells (A) and MDA-MB-231 cells (B) were treated with
different constant concentrations of tetrac (10
29 to 10
25 M). Cells were harvested and counted at intervals as indicated. Total cell numbers from each
treatment were used as indicators of tetrac-induced anti-proliferation. Multiple observations at each time point are multiple cell counts from one
experiment.
doi:10.1371/journal.pcbi.1001073.g003
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12 d of tetrac treatment. The degree of apoptosis induced by
10
26 M nano-tetrac was 3-fold that of 10
26 M tetrac (Fig. 6C).
We have recently reported that tetrac and nano-tetrac induce
gene expression profile changes in MDA-MB cells [8] and
medullary thyroid carcinoma cells [9]. Experiments presented
here examined pro-apoptotic gene expression in tetrac- and nano-
tetrac-treated glioblastoma U87MG cells and MDA-MB cells in
the perfusion bellows cell culture system. RNA was extracted from
the harvested cells at the end of treatment for RT-PCR studies.
Treatment of cells for 2 d with nano-tetrac (10
26 M) increased
expression of PIG3, BAD, p21 and p53 in both U87MG and MDA-
MB cells (Fig. 7). In contrast, tetrac (10
26 M) did not significantly
increase expression of this panel of genes in U87MG cells and,
except for c-jun, gene expression in the MDA-MB cells was
enhanced to a lesser extent by tetrac than by nano-tetrac. We have
previously observed several differences between gene expression
profiles that result from treatment with unmodified tetrac and
nano-tetrac [9].
Experiments of flow cytometry and gene expression demon-
strate the practicality of harvesting tumor cells from polymer flakes
in the perfusion bellows cell culture system for studies of post-
treatment states of the cells.
Lack of effects of tetrac and nano-tetrac on non-
malignant cells
We also determined whether tetrac and nano-tetrac had anti-
proliferative actions on immortalized non-malignant cells. Monkey
kidney epithelial CV-1 cells and human embryonic kidney 293T
cells were treated daily with 10
26 M tetrac or 10
26 M nano-tetrac
for 7 d. There was no significant change in cell numbers or
morphology (results not shown here) when untreated cells were
compared with those exposed to tetrac or nano-tetrac.
Combined resveratrol and tetrac exposure and cancer
cell proliferation
A naturally-occurring stilbene, resveratrol [14], induces apop-
tosis in human follicular thyroid cancer cells [4,17]. Thyroid
hormone analogue T4 inhibits the apoptotic action of resveratrol
[3,4] and tetrac has been shown to restore the pro-apoptotic effect
of the stilbene in presence of T4 [3]. This effect of tetrac reflects
displacement by tetrac of T4 from the iodothyronine receptor site
on integrin avb3. Resveratrol is capable of binding to the integrin
avb3 [3,18], at a site distinct from that for tetrac and other thyroid
hormone analogues [3,4]. In the present studies, the anti-
proliferative effect of combined resveratrol and tetrac exposure
Table 1. Parameter estimates and their uncertainty for effects of tetrac formulations on proliferation of cancer cells (all results
from NONMEM).
Effect on rate of growth Effect on success of replication
Cell line Formulation Imaxk IC50k (mM) ImaxR kiR (day
21) IC50R (mM)
U87MG Tetrac Estimate 0.57 0.047 0.92 - 47.4
P50, P10–P90 0.55 0.054 0.91 - 44.2
(rich sampling) 0.52–0.59 0.036–0.072 0.78–0.97 - 37.3–53.2
P50, P10–P90 0.58 0.047 0.91 - 42.4
(actual times) 0.54–0.62 0.027–0.077 0.79–0.98 - 35.7–55.2
U87MG Nano-tetrac Estimate 0.33 0.0001
a 1.0
b 0.92 0.074
P50, P10–P90 0.33 0.0001
a 1.0
b,c 0.91 0.075
(rich sampling) 0.31–0.35 - - 0.84–0.98 0.057–0.097
P50, P10–P90 0.39 0.0001
a 1.0
b,c 0.88 0.055
(actual times) 0.32–0.46 - - 0.76–1.1 0.026–0.126
MDA-MB Tetrac Estimate 0.85 5.1 0.20 - 0.087
P50, P10–P90 0.85 5.0 0.20 - 0.091
(rich sampling) 0.84–0.86 4.6–5.4 0.19–0.20 - 0.083–0.099
P50, P10–P90 0.85 4.8 0.19 - 0.075
(actual times) 0.81–0.91 3.7–6.4 0.18–0.20 - 0.059–0.098
MDA-MB Nano-tetrac Estimate 1.0 6.3 1.0
b 1.2 0.0086
P50, P10–P90 1.0
b,c 6.5 1.0
b,c 1.2 0.0085
(rich sampling) - 5.6–7.5 - 1.1–1.3 0.0075–0.010
P50, P10–P90 1.0
b,c 10.3 1.0
b,c 1.1 0.0069
(actual times) - 5.0–131 - 0.93–1.2 0.0039–0.013
MDAMB: MDA-MB-231; P50, P10, P90: median, 10% and 90% percentile from bootstrap runs.
The IC50 estimates for nano-tetrac are hypothetical concentrations that assume all of the tetrac bound to the nanoparticle is available for binding to the integrin
receptor.
The bootstraps were run both with a rich sampling design (n=50 datasets) and the sampling times used in the actual experiments (n=100 datasets).
aFixed to 0.0001 mM as it was estimated very low and the lowest studied concentration was 0.001 mM.
bImaxR at time=0 d; ImaxR decreases with time (ImaxR=ImaxR0 ? e
2kiR ? time), possibly due to functional adaptation of cells or the presence of two or more
subpopulations with different sensitivities to tetrac.
cFixed for the bootstrap.
-not applicable.
doi:10.1371/journal.pcbi.1001073.t001
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presence or absence of 10
27 M tetrac. Both tetrac and resveratrol
individually caused anti-proliferative effects in MDA-MB cells
(Fig. 8A), while their combination was additive, based on
comparison of cell counts on day 8 and Loewe additivity. Human
follicular thyroid cancer (FTC) cells were treated daily with
resveratrol (0.1 mM) in presence or absence of 10
27 M tetrac.
Compared with breast cancer cells, FTC236 cells were less
sensitive to tetrac (Fig. 8B). The inhibitory effects of resveratrol
and tetrac in combination were additive also in FTC cells, based
on cell counts on day 10.
Tetrac increases the anti-proliferative action of
cetuximab in human breast cancer cells
Cetuximab is a monoclonal antibody targeted to the
extracellular domain of the EGFR intended for use in patients
with metastatic colorectal carcinoma and certain other tumors
[19,20]. Effectiveness is variable [21,22]. The drug has been
combined clinically with various other chemotherapeutic agents
in colorectal cancer patients [21,22] and recently has been
tested adjunctively in vitro against breast cancer cells [23].
Combining cetuximab with various chemotherapeutic agents
has revealed additive or potentiated growth inhibition in various
cancer cell lines [21,22]. To determine whether tetrac
potentiates cetuximab-induced anti-proliferation, human breast
cancer MDA-MB cells were treated with cetuximab (0.1 mg/
mL) in presence or absence of 10
27 M tetrac. Individually, both
agents suppressed proliferation of MDA-MB cells (Fig. 9A).
After 8 d treatment with cetuximab and tetrac the average total
cell counts were decreased by 34% and 38%, compared to
control. Combined tetrac and cetuximab was more effective,
reducing total cell numbers on average by 63%. Application of
an empirical mathematical model to all treatments and time
points simultaneously also suggested an approximately additive
effect of both compounds. The empirical model was a disease
progression type model where the cell counts in the control
treatment were described by a simple exponential function. The
effect of tetrac was described as an offset, i.e. a change from
baseline cell counts while tetrac is present. The effect of
cetuximab was described in the same way, only including an
additional lag-time of effect. When both drug effects were added
the resulting profile adequately described the cell counts during
combination treatment for the studied concentrations and
observation period.
Figure 4. Tetrac and nano-tetrac suppress cell proliferation. (A) MDA-MB-231 cells were treated with two constant concentrations of either
tetrac or nano-tetrac (10
26 and 2.5610
26 M) and cells harvested at the time points indicated. Total cell numbers from each treatment were used as
indicators of tetrac- or nano-tetrac-induced anti-proliferation. Nano-tetrac appeared more effective. (B) MDA-MB-231 cells were treated with constant
concentrations of 10
29 to 10
25 M nano-tetrac and cells harvested at the time points indicated. Total cell counts from each treatment were used as
indicators of anti-proliferative effect. Model-fitted lines are shown. (C) The effect of nano-tetrac (10
29–10
26 M) on proliferation of U87MG glioma cells
is shown. As with MDA-MB-231 cells in (B), a concentration-dependent effect was obtained. Multiple observations at each time point represent
results from 3 repeat experiments. Error bars in Fig. 4A are standard deviations from 3 experiments.
doi:10.1371/journal.pcbi.1001073.g004
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cetuximab in colon cancer cells
An approximately additive effect was also found for the
combination of nano-tetrac and cetuximab in human colon
cancer Colo-205 cells (Fig 9 B). Colo-205 cells grown in T-75 flask
were treated with either nano-tetrac (10
28 and 10
27 M),
cetuximab (4 and 40 mg/ml), or combination. Medium was
refreshed with agents daily. Cells were harvested and counted as
indicated up to 16 days. A model including effects of both drugs on
the probability of successful replication and a noncompetitive
interaction adequately described the observed cell counts (Figs. 9B
and 9C). The effect of the combination treatments was slightly
larger than predicted by a competitive interaction model, where
both drugs work on the same pathway, and slightly smaller than
predicted by a purely noncompetitive interaction model, where the
drug works on completely different pathways. Therefore a factor y
was included (see equation in the Materials and Methods section)
which was estimated at 5.6. The ImaxR and IC50R for inhibition
of the probability of successful replication were 0.12 and 7.0 nM
for nano-tetrac and 0.13 and 3.3 mg/mL for cetuximab.
Discussion
Using a novel perfusion bellows cell culture system developed in
our laboratory (Fig. 1), we have compared the pharmacodynamics
in vitro of unmodified and nanoparticulate formulations of tetrac as
anti-proliferative agents. The system revealed that nano-tetrac had
a higher potency than tetrac as an anti-proliferative agent (Fig. 4).
Neither nano-tetrac nor tetrac affected proliferation of two non-
cancer cell lines even at high concentrations (10
26 M).
The anti-proliferative effect of tetrac and nano-tetrac on cancer
cells in the perfusion bellows cell culture system was seen starting
3 d after start of treatment (Fig. 3, 4). The anti-cancer effects of
tetrac and nano-tetrac in human tumor cell xenografts were well-
established within 3 d after onset of drug administration [9]. These
results in the perfusion system thus reproduce findings obtained
earlier in cells grown in culture dishes and xenografts. While the
tetrac effects in xenografts have been shown to involve both
primary effects on tumor cell proliferation and an anti-angiogen-
esis effect [6], the effect of tetrac and nano-tetrac in the perfusion
bellows cell culture system of course is limited to suppression of cell
proliferation.
In vitro models such as described here can save animals by
decreasing the number of animal studies which need to be
conducted, by employing well-defined conditions which allow for
investigation of individual factors impacting the PD and
permitting the simulation of human pharmacokinetics (PK) based
on data from clinical trials. Limitations of the method described
here which need to be considered are that the impact of tissue
penetration and the effect of the immune system are usually not
directly taken into account; PK/PD models based on animal or
clinical studies that include measurement of drug concentrations in
tumor need to be developed.
In the perfusion system cells are exposed alternately to fresh
medium and air. This paradigm optimizes growth conditions for
cancer cells by maximizing nutrient uptake and oxygen transfer
and supported experiments of up to 3 weeks’ duration (Fig. 3B).
Information obtained in longer studies about both the slope of the
growth/proliferation phase and the plateau of the cell count with
regard to time permitted mathematical modeling to identify two
Figure 5. Goodness of fit plots. Observed versus predicted cell counts from NONMEM for the effect of unmodified tetrac on (A) U87MG and (B)
MDA-MB-231 cells and the effect of tetrac nanoparticles on (C) U87MG and (D) MDA-MB-231 cells.
doi:10.1371/journal.pcbi.1001073.g005
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and inhibition of success of replication (Fig. 2).
In addition to treating the cells with constant drug concentra-
tions, reflecting in vivo continuous infusion treatment, the in vitro
system described here allows to study other dosing regimens.
Multiple short-term or intermittent infusions or brief injections can
be studied in the perfusion system by adjusting the flow rate of the
medium and the dosing schedule. Drug concentration/time
profiles that are expected or have been obtained in human or
animal studies can be simulated and effects on cancer cells of
changing drug concentrations as anticipated in vivo may be
observed in the system. Together with mathematical modeling,
these in vitro paradigms can support optimization of design of
subsequent animal and human studies thereby saving time and
expense. Because a wider range of drug concentrations can be
studied in vitro than in animal models, dose selection for in vivo
studies may become more efficient.
Mathematical modeling was utilized to increase the amount of
information gained from the reported experiments. By considering
the entire time course of cell counts in response to multiple
Figure 6. Tetrac induces apoptosis in MDA-MB-231 cells. (A) MDA-MB-231 cells grown in the perfusion bellows cell culture system were
treated with different constant concentrations of tetrac (10
27 Mt o1 0
25 M) for 12 d, and harvested on the days indicated. Two million cells from
each sample were prepared for flow cytometry as described in the Materials and Methods section. Over 1–3 d treatment with these 4 concentrations
of tetrac, the percentages of cells in G1, S or G2/M phases remained approximately the same, while TUNEL levels rose, particularly with the highest
tetrac concentration, to 90% of the cells examined by day 3. (B) By days 11 and 12, the percentage of cells in phase G1 remained at approximately
40% except for cells exposed to the highest nano-tetrac concentration (20% in phase G1); TUNEL levels rose at the same concentration. Percentages
of cells in G2/M and S phases were relatively constant. (C) Increases in TUNEL reactivity were not remarkable with either 10
26 or 10
25 M tetrac,
whereas 10
26 M nano-tetrac caused a 3-fold increase in apoptosis. These results, obtained after exposure of cells to tetrac formulations for 3 d,
confirm prior studies showing that nano-tetrac is more effective than tetrac at similar concentrations in causing changes consistent with a pro-
apoptotic effect on cancer cells [8,9].
doi:10.1371/journal.pcbi.1001073.g006
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more insight can be gained into the dose-response relationship and
mechanism of action of a drug. Purely empirical growth models,
e.g., the Weibull model, often do not include meaningful
parameters, but offer arbitrary coefficients. For simulating other
scenarios, e.g., cells with faster growth rates, mechanism-based
models may be more adequate. While only total cell counts were
available in the perfusion bellows cell culture system experiments
reported here the applied model is based on mechanisms of action.
Inclusion of flow cytometry results in the model will be performed
for future experiments in order to enhance the mechanism-based
modeling approach.
For U87MG cells studied here, mathematical modeling
suggested a higher maximum effect but lower sensitivity of the
effect on probability of successful replication, compared to the
effect on growth rate for both unmodified and nano-tetrac. For
both effects the sensitivity favored nano-tetrac over unmodified
tetrac. This may be explained by the ability of unmodified tetrac to
penetrate into cells and thereby exert low-grade thyromimetic
(proliferative) effects in addition to the anti-proliferative effects
initiated at the cell surface integrin receptor. Therefore the net
anti-proliferative effect of unmodified tetrac is decreased. The
model describes the net effects of unmodified tetrac. Nano-tetrac
does not gain access to the cell interior and shows a more robust
anti-proliferative effect.
MDA-MB cells had growth rate sensitivity to nano-tetrac that
was similar to unmodified tetrac, but a higher sensitivity to nano-
tetrac for the effect on success of replication. For both unmodified
tetrac and nano-tetrac MDA-MB cells were more sensitive to the
effect on success of replication than the effect on growth rate. The
uncertainty of the parameter estimates was explored by bootstrap
runs. A very rich sampling design was used to ensure the general
estimability of the model by two different algorithms. In addition,
the estimability was tested under the sampling designs of the actual
experiments. For the models of unmodified tetrac, the 10%
percentile to 90% percentile intervals (P10–P90) were relatively
narrow. A larger uncertainty was seen for the IC50 parameters in
the nano-tetrac models, especially for the IC50k in MDA-MB
cells. The latter suggests that the effect on rate of growth was not
apparent in all of the randomly created bootstrap datasets.
Optimal design was not applied to structuring those experiments
but will be utilized in future studies. It is important to note that the
studied concentrations were 10-fold different between the
treatment arms and, based on that factor, the uncertainties in
IC50 and the differences in the estimates between NONMEM and
S-ADAPT are acceptable. Overall our mechanism-based models
have adequately described the cell counts over time in our studies
and the effects of a wide range of tetrac concentrations and will
support the design of future experiments. In addition to the
pharmacodynamic studies in vitro and in animals, also the
pharmacokinetics of tetrac will be studied in vivo to more fully
characterize the pharmacokinetic / pharmacodynamic relation-
ship for tetrac in vivo.
We have previously shown that resveratrol induces apoptosis in
human cancer cells, an effect which requires the nuclear
translocation of COX-2 and activated ERK1/2 for support of
Figure 7. Expression of pro-apoptotic genes by tetrac and nano-tetrac. (A) U87MG human glioblastoma cells and (B) MDA-MB-231 breast
cancer cells were treated with constant concentrations of 10
26 M tetrac or nano-tetrac in the perfusion bellows cell culture system. Cells were
harvested after 2 d of treatment and total RNA was extracted. RT-PCR was carried out as described in the Materials and Methods section. Nano-tetrac
significantly stimulated (P,0.02) the expression of pro-apoptotic genes (p53, BAD, PIG3, p21) [34,35] in U87MG cells, while unmodified tetrac was
effective only as an inducer of expression of c-jun. The results in MDA-MB-231 cells were different, in that tetrac enhanced the expression of c-jun, c-
fos and p21 (each, P,0.05 vs. control) to a moderate degree. Nano-tetrac induced expression of BAD (P=0.001), PIG3 (P=0.037) and p21 (P=0.05).
Together, results in the figure demonstrate the variable nature of responses to tetrac in the two cell lines and a more consistent response of each cell
line to nano-tetrac.
doi:10.1371/journal.pcbi.1001073.g007
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to plasma membrane integrin avb3 [1,18], but at discrete sites that
apparently do not interfere with one another [3,7]. In the present
studies, the combination of resveratrol and tetrac was additive in
the in vitro perfusion bellows cell culture system in terms of
suppression of cell proliferation in two human cancer cell lines.
The ability to detect such additivity—or potentiation, if present—
is obviously a requirement of the perfusion system.
Therapeutic epidermal growth factor receptor (EGFR) targeting
with cetuximab, either as single agent or in combination with
chemotherapy, has demonstrated variable clinical activity [19] and
may benefit only select patients [20]. In the perfusion bellows cell
culture system, concurrent treatment with tetrac and cetuximab
resulted in highly effective inhibition of proliferation of MDA-MB
cells by day 8 (Fig. 9A). The model system thus offers the prospect
of efficiently exploring a variety of drug combinations. An
empirical disease progression model was employed for the
combination treatment of MDA-MB cells with tetrac and
cetuximab, and revealed an approximately additive effect for the
combination. While such an empirical model has limitations it is
not feasible to develop a receptor occupancy model for a drug
combination without data at multiple drug concentrations. Two
concentrations each of nano-tetrac and cetuximab and all four
combinations were studied in Colo-205 cells in cell culture flasks.
The effects of nano-tetrac and cetuximab were adequately
described as inhibition of the probability of successful replication.
Modeling of all treatment arms simultaneously revealed an
approximately additive effect of the combination. The effect of
the combination treatment was slightly smaller than predicted by a
purely noncompetitive interaction and slightly larger than
predicted by a purely competitive interaction model. This suggests
that there is a partial overlap between the mechanisms and
pathways of action of nano-tetrac and cetuximab. That interpre-
tation of the modeling results is supported by previous studies in
our laboratory where we showed that tetrac interferes with
crosstalk between the cell surface receptor for thyroid hormone
and EGFR [24] and it can be assumed with confidence that nano-
tetrac also interferes with this crosstalk. In addition, nano-tetrac,
but not unmodified tetrac, decreases the expression of the EGFR
gene [8]. For this study in cell culture flasks it was observed that
cell counts in all treatment arms decreased noticeably and
approximately in parallel after Day 6 (Fig 9B) which cannot be
attributed to drug effect. Such observations further support the use
of the perfusion bellows cell culture system which provides optimal
nutrient uptake and oxygen transfer for the cells and will be
utilized for future combination studies in colon cancer cells.
The perfusion bellows cell culture studies we described provide
useful pharmacodynamic information on the application of new
drugs or combinations of various agents in vitro to human cancer
cell lines. In combination with pharmacodynamic modeling and
by including information about the expected pharmacokinetics of
a drug, the perfusion bellows cell culture system permits study of
the dose-response relationships of anti-neoplastic agents over a
very wide concentration range in vitro, and can support
translation from in vitro models to animal models and human
clinical trials.
Materials and Methods
Cell lines
Human glioblastoma cells (U87MG), human breast cancer
MDA-MB-231 cells (MDAMB), human colon cancer Colo-205
cells, African green monkey kidney epithelial CV-1 cells and
human embryonic kidney 293T cells were purchased from ATCC.
Human follicular thyroid cancer FTC236 cells were generously
provided by Dr. Orlo Clark (University of California at San
Francisco-Mt. Zion Medical Center, San Francisco, CA). U87MG
cells were maintained for study in MEM (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS, Sigma Aldrich,
St. Louis, MO). Colo-205 cells were maintained in RPMI (Gibco)
supplemented with 10% FBS. MDA-MB, CV-1 and 293T cells
were maintained in DMEM (Gibco) supplemented with 10% FBS.
Follicular thyroid cancer cells were supported in 50% DMEM/
50% Ham’s F-12 (Gibco) plus 10 mU/ml of TSH (Sigma Aldrich).
Cells were cultured in a 5% CO2/95% air incubator at 37uC.
Figure 8. Effect of tetrac on resveratrol-induced anti-prolifer-
ation in human cancer cells. (A) Human breast cancer estrogen
receptor-negative MDA-MB-231 cells were treated with constant
concentrations of resveratrol (0.1 mM) and/or tetrac (10
27 M) in the
perfusion bellows cell culture system. Cell aliquots were harvested daily
for counting. Both agents individually caused suppression of cell
proliferation and together they caused an additive effect. (B) Human
follicular thyroid cancer FTC236 cells were treated daily with resveratrol
(0.1 mM) and/or 10
27 M tetrac in the perfusion bellows cell culture
system. Cell aliquots were again harvested daily for cell counting. At 8
and 10 d, based on both unadjusted and Holm t tests, the following
results were obtained: tetrac+resveratrol, P,0.05 (unadjusted t test)
and P=0.066 (Holm t test). *, P,0.05 including a-adjustment for six
comparisons (Holm t test). Multiple observations at each time point are
multiple cell counts from one experiment.
doi:10.1371/journal.pcbi.1001073.g008
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Shown in Fig. 1 is a newly developed perfusion bellows cell
culture system that is a disposable bioreactor capable of
high density cell culture for studies of anti-cancer drugs.
Each cell culture system is a compressible (bellows) 500 mL
bottle that contains cell culture medium and specially-treated
polymer flakes to which cells spontaneously attach and
then proliferate. Through moving bellows and porous mem-
branes the level of the medium in the bottle changes
periodically. Consequently, the cells are alternately submerged
in the culture medium and exposed to 5% CO2/95% air which
creates a dynamic interface between air and medium on the
plated cell surface that maximizes nutrient uptake and oxygen
transfer. The system provides a low shear, high aeration and
foam-free culture environment. Proprietary treatment of
the surfaces of the flakes enables seating and the harvesting of
cells and secreted proteins are readily isolated from the
perfusate.
In a non-perfusion bellows cell culture system that was also
used, the medium in each bottle was replaced by fresh medium
every 24 h. In the perfusion bellows cell culture system, medium
was progressively refreshed over 24 h, so that one complete
change of medium occurred over 24 h.
To establish the cultures, 5610
7 cells were seeded in
perfusion and non-perfusion bellows bottles and incubated
overnight at 37uC. Flakes were then harvested, trypsinized,
and the cells were collected and counted. The number of
cells that attached to flakes was 10–15610
6 per bottle. For
experiments, the perfusion bellows cell culture system was run
for 2 d prior to starting the experiments. The cell numbers at
this point were about 30–50610
6 cells per bottle. Cultured
cells were then exposed to 1% FBS-containing medium. Tetrac
or nano-tetrac was added to the medium in the reservoir bottle
to achieve the final concentrations reported for each experi-
ment.
Nano-tetrac utilized in the studies of proliferation of MDA-
MB, U87MG, and Colo-205 cells was manufactured on
contract by Azopharma (Miramar, FL). Nano-tetrac for
all other experiments was prepared at the Pharmaceutical
Research Institute, Rensselaer, NY [9]. Unmodified tetrac
was synthesized on contract by Peptido GmbH (Bexbach,
Germany).
Figure 9. Effect of tetrac and nano-tetrac on cetuximab-induced anti-proliferation. (A) Human breast cancer MDA-MB-231 cells were
treated with constant concentrations of 0.1 mg/mL of cetuximab in the presence or absence of 10
27 M tetrac in the perfusion bellows cell culture
system for 8 d. Aliquots of cells were harvested and counted at the indicated time points. Levels of significance based on unadjusted t test (Holm t
test) were the following: cetuximab, alone, vs. control at 6 d, P=0.13 (0.13), and at 8 d, P=0.006 (0.025); tetrac alone vs. control at 6 d, P=0.052
(0.10), and at 8 d, P=0.0004 (0.002); cetuximab + tetrac vs. control at 6 d, P=0.008 (0.023), and at 8 d, P 0.0004 (0.002). *, P,0.05 including a-
adjustment for six comparisons (Holm t test). Multiple observations at each time point are multiple cell counts from one experiment. (B) Colo 205
cells in cell culture flasks were treated with two different constant concentrations of nano-tetrac and cetuximab, alone or in combination. Multiple
observations at each time point are multiple cell counts from one experiment. Lines are model fitted cell counts. (C) Observed versus predicted cell
counts corresponding to the experiment and modeling shown in (B).
doi:10.1371/journal.pcbi.1001073.g009
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(LC/MS/MS)
In LC/MS/MS experiments, medium samples (20 mL) were
injected onto an HP 1100 series HPLC system (Agilent
Technologies, Palo Alto, CA, USA), equipped with a narrow-
bore Zorbax Eclipse XDB-C18 column (5 mm, 15062.1 mm;
Agilent). Separation was performed using a mobile phase of 0.1%
(v/v) acetic acid (A) and 100% acetonitrile (B), with a linear
gradient of 20–60% B over 25 min. Flow rate was maintained at
0.2 mL min
21 and elution was monitored by a diode array
detector (200–600 nm). The LC effluent was then introduced into
a turbo ion-spray source on a Q/STAR-XL quadruple/time-of-
flight (TOF) hybrid mass spectrometer (Applied Biosystems, Foster
City, CA, USA). Negative ESI mass spectra were acquired over
the range m/z 100 to 400. The electrospray voltage was set at
24.5 kV and the source temperature was maintained at 475uC.
CID spectra were acquired using nitrogen as the collision gas
under collision energies of 25–55 V. High purity nitrogen gas
(99.995%) was used as the nebulizer, curtain, heater and collision
gas source.
RT-PCR
Total RNA was isolated as described previously [25–27]. First
strand complementary DNAs were synthesized from 1 mg of total
RNA, using oligo dT and AMV Reverse Transcriptase (Promega,
Madison, WI). First-strand cDNA templates were amplified for
GAPDH, c-fos, PIG3, c-Jun, and BAD mRNAs by polymerase chain
reaction (PCR), using a hot start (Ampliwax, Perkin Elmer, Foster
City, CA). Primer sequences were GAPDH (59-AAGAAGATG-
CGGCTGACTGTCGAGCCACA-39 [forward] and 59- TCTC-
ATGGTTCACACCCATGACGAACATG-39 [reverse), c-fos (59-
GAATAAGATGGCTGCAGCCAAATGCCGCAA-39[forward]
and 59-CAGTCA-GATCAAGGGAAGCACAGACATCT-39
[reverse]), PIG3 (59-TGGTCACAG-CTGGCTCCCAGAA-39
[forward] and 59-CCGTGGAGAAGTGAGGCAGAATTT-39
[reverse]), c-jun (59-GGAAACGACCTTCTATGACGATGCCC-
TCAA-39 [forward] and 59-GAACCCCTCCTGCTCATCTGT-
CACGTTCTT-39 [reverse) and BAD (59-GTT-TGAGCCGAG-
TGAGCAGG-39 [forward] and 59-ATAGCGCTGTGCTGCC-
CAGA-39 [reverse]). The PCR cycle was an initial step of 95uC for
3 min, followed by 94uC for 1 min, 55uC for 1 min, 72uC for
1 min, then 25 cycles and a final cycle of 72uC for 8 min. PCR
products were separated by electrophoresis through 2% agarose
gels containing 0.2 mg of ethidium bromide/mL. Gels were
visualized under UV light and photographed with Polaroid film
(Polaroid Co., Cambridge, MA). Photographs were scanned under
direct light for quantitation and illustration. Results from PCR
products were normalized to the GAPDH signal.
Flow cytometry analysis
Cells were harvested from flakes by trypsinization, washed with
PBS, fixed in ice-cold 70% ethanol and stored in a freezer
overnight. Cells were labeled to detect apoptosis with the In situ
Cell Death Detection Kit, Fluorescein (Roche Diagnostics
Corporation, Roche Applied Science, Indianapolis, IN). The
recommended procedures were used with modifications in
permeabilization time and temperature to improve results. Fixed
cells were centrifuged and washed once in PBS containing 1%
bovine serum albumin (BSA), then resuspended in 2 mL
permeabilization buffer (0.1% Triton X-100 and 0.1% sodium
citrate in PBS) for 25 min at room temperature, followed by a
wash in 0.5 mL PBS/1% BSA. Cells were resuspended in 50 mL
TUNEL reaction mixture (TdT enzyme and labeling solution) and
placed in an incubator for 60 min at 37uC in a humidified dark
atmosphere. Labeled cells were washed in PBS/1% BSA, then
resuspended in 0.5 mL ice-cold PBS/0/1% BSA Triton X-100
that contained 1 mg/mL 49, 6-diamidino-2-phenylindole (DAPI)
for at 20 min. Cell samples were analyzed with a BD
TM LSR II
(BD Biosciences, San Jose, CA), using BD FACSDiva
TM software.
Fluorescence histograms were gated on forward scatter (FSC) and
side scatter (SSC) to exclude debris and clumped cells. Gating on
height vs. area fluorescence of DAPI signal was set to eliminate
clumped cells and to obtain the singlet population for analyzing
the cell cycle phase ratios in G1, S or G2/M.
Statistical analysis
Immunoblot and nucleotide densities were measured with a
Storm 860 phosphorimager, followed by analysis with Image-
Quant software (Molecular Dynamics, Sunnyvale, CA). Student’s t
test, with P,0.05 as the threshold for significance, was used to
evaluate the significance of the hormone and inhibitor effects.
Where cell counts were tested for statistical significance, the data
were log-transformed prior to testing. For the cell count data, an
a-adjustment to account for multiple comparisons was utilized
according to the Holm t test. The concept of Loewe additivity [28]
was applied to cell count data from combination treatments. For
experiments involving cells counts at many time points, for
multiple treatments, or both, multiple t tests were not an adequate
method of analysis due to the large number of comparisons. In
addition, multiple comparison tests treat the observations at each
time point independently, whereas mathematical modeling, as
described below, takes into account the full time course. Observed
data are presented in the figures as individual data points or
average 6 standard deviation (SD).
Mathematical modeling
The time course of cell counts of the several cancer cell lines
treated with different concentrations of tetrac or nano-tetrac (or a
combination of tetrac with cetuximab or resveratrol, or nano-
tetrac with cetuximab) was modeled utilizing a naı ¨ve pooled
approach in NONMEM VI (version 6.2). The pooled approach
does not distinguish any potential unexplained variability between
the bottles (treatment arms) from general assay error, e.g.,
uncertainty in cell counts, but expresses both in the residual
error. The perfusion bellows cell culture system experiments
included one bottle per treatment arm with the multiple
observations per time point being different cell counts of one
sample for the tetrac experiments and the nano-tetrac with
cetuximab combination study, and average cell counts from three
studies for the nano-tetrac experiments. The population approach
in NONMEM (FOCE) did not succeed in distinguishing inter-
subject variability (variability between bottles) and unexplained
random variability (e.g. general assay error). The naı ¨ve pooled
analysis in NONMEM was equivalent to a pooled analysis using
the Maximum Likelihood approach in ADAPT, for example. S-
ADAPT was also utilized as described below in order to make use
of the MC-PEM algorithm and for additional model evaluation.
All time points and treatment arms within each experiment were
modeled simultaneously. A mechanism-based model [29] was
adapted to describe the proliferation of cancer cells and the
inhibition of proliferation by tetrac. This model assumes two
populations of cells in different phases of the cell cycle: cells that
are preparing for replication (phase 1) and cells that are
immediately ‘pre-replication’ (phase 2). Cells transition from
phase 1 to phase 2 by a first-order growth rate constant, while
replication from phase 2 to phase 1 is assumed to be fast (Fig. 2).
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dC1
dt
~Re p:InhR:k21:C2{k12:Inhk:C1
dC2
dt
~{k21:C2zk12:Inhk:C1
Ct~C1zC2
where C1 is the number of cells in phase 1, C2the number of cells in
phase 2, k21 the first order rate constant for replication (transition
from phase 2 to phase 1), and k12 the first-order growth rate
constant for transition from phase 1 to phase 2. The k21 was
assumed to be fast and therefore was fixed to 100 day
21,w h i c h
resulted ina ratioofk21/k12 of approximately 50 to100,depending
upon the cell line. The total number of cells Ct is the sum of C1 and
C2. Rep is the replication efficiency factor which is described by:
Re p~2: 1{
Ct
CmaxzCt

where Cmax is the maximum number of cells. Without tetrac (or
nano-tetrac), the replication efficiency factor approaches 2, which
reflects a 100% probability of successful replication. When Ct
approachesCmax,Repapproaches1,representinga 0%probability
of net replication, that is, cells in reality still transition between the
phases, but the number of cells does not increase further. The InhR
describes the inhibitory effect of tetrac on the probability of
successful replication:
InhR~ 1{
ImaxR:Tetrac
IC50RzTetrac

where ImaxR is the maximum effect of tetrac (or nano-tetrac) on the
probability of successful replication and IC50R is the tetrac
concentration needed to achieve a half-maximal effect. In the case
of InhR, 0.50, this effect results in cell killing, as it then follows that
Rep N InhR, 1.0. The latter case also illustrates that cells which do
not replicate successfully are eliminated in this process. For some
studies, inclusion of a decrease in ImaxR over time was necessary in
order to adequately describe the data:
ImaxR~ImaxR0:e{kiR:time
where ImaxR0 is the ImaxR at time=0 and kiR is a constant
describing the decrease of ImaxR over time.
Inhk describes the inhibitory effect of tetrac on the rate of
growth:
Inhk~ 1{
Imaxk:Tetrac
IC50kzTetrac

where Imaxk is the maximum effect of tetrac on rate of growth
and IC50k is the tetrac concentration needed to achieve a half-
maximal effect. Both IC50R and IC50k are measures for the
sensitivity of the cancer cells to the effects of tetrac. A low IC50
corresponds to a high sensitivity of the cells to a particular drug
effect, and vice versa. While the InhR describes an irreversible
removal of cells from the cell cycle, Inhk only slows down the
transitioning of cells through the cell cycle. The cells remain in
state 1 for a longer period of time which represents growth and
preparation for replication. This is reflected in a decreased slope of
the growth curve.
Although cells in state 1 and state 2 were not measured
separately in the perfusion bellows cell culture system experiments
reported here, the two effects were distinguishable and the
parameters estimable. The effect on rate of growth decreases the
slope of the growth curves whereas the effect on successful
replication results in lower plateaus at the end of the growth curves
for the treatment arms compared to control. As described below
simulation estimation runs were performed to confirm the
estimability of the parameters.
The effects of nano-tetrac were modeled by the same equations
as described above for unmodified tetrac. However the IC50
estimates for nano-tetrac are hypothetical concentrations that
assume all of the tetrac bound to the nanoparticle is available for
binding to the integrin receptor.
A lag time for growth was included in order to describe the data
successfully. The parameter k12 was low at the start of the
experiment and increased over time:
k12~k12max: 1{e{ b:time ðÞ c 
Here, k12max is the maximum growth rate constant and b and c
are empirical constants. The residual variability was described by
an additive error on log-scale.
A model for non-competitive interaction was applied to the
experiment on the effects of nano-tetrac, cetuximab, and their
combination on Colo-205 cells. The effects of nano-tetrac
(InhRNPT) and cetuximab (InhRCET) were described as:
InhRNPT~
ImaxRNPT :Nano{tetrac
IC50RNPTzNano{tetrac
InhRCET~
ImaxRCET :Cetuximab
IC50RCETzCetuximab
The effect of the combination was:
InhRNPT CET~1{InhRNPT{InhRCETzy:InhRNPT:InhRCET
which describes a non-competitive interaction [30,31] when y=1,
that is both drugs act by completely separate pathways [32,33].
When y.1, then the effect of the combination is less than would
be expected from two drugs acting completely independent of each
other. The decrease of cell counts in all treatment arms towards
the end of the observation period in this study in cell culture flasks
was modeled by a series of transit compartments.
Model discrimination was based on comparison of the objective
function in NONMEM, visual comparisons of observed and fitted
cell counts over time, and observed vs. fitted plots. Simulation
estimation experiments (bootstraps) were performed for the models
of tetrac and nano-tetrac effects on U87MG and MDA-MB cells
in order to explore the estimability of the model and the bias and
uncertainty in the parameter estimates. The simulations were done
in Berkeley Madonna (v.8.3.14). The estimations were performed
in both NONMEM (pooled approach) and the MC-PEM (Monte
Carlo parametric expectation maximization) algorithm in paralle-
lized S-ADAPT (v.1.56). One hundred bootstrap datasets in
NONMEM and fifty bootstrap datasets in S-ADAPT, each with
10 profiles per treatment arm, were run for each of the four
experiments (two cell lines and two formulations), assuming a very
rich sampling schedule and an additive error on log-scale of 0.1
(Bootstraps based on additive errors on log-scale of 0.02, 0.05, and
0.1 had been previously conducted for the model of tetrac effects
in U87MG cells). As the bootstraps were performed in order to
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their distribution, and also due to long run times, 50 to 100
bootstrap runs each were adequate. Those bootstraps based on the
rich sampling schedule were conducted to evaluate the mathe-
matical estimability of the model parameters under ideal
experimental conditions, i.e. many sampling time points. One
hundred bootstrap datasets each with 10 profiles per treatment
arm were run in NONMEM for each of the four models with the
sampling schedules that were actually used in the experiments and
assuming an additive error on log-scale of 0.1. The bootstraps
based on the actual sampling schedules were performed to test
whether the model parameters were well-estimable based on both
the model and the experimental conditions. The median and 10%
and 90% percentiles were calculated from each of those simulation
estimation experiments.
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